Phibro Animal Health Corporation
Price Action
Technical Summary
STAGE 2 UPTRENDPhibro Animal Health Corporation is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 82), indicating clear outperformance against the broad market. Earnings growth of 7% provides fundamental context to the price action. Investors should exercise caution due to high volatility (52% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $55.83 | +5.04% | ABOVE |
| 50 SMA | $54.12 | +8.35% | ABOVE |
| 100 SMA | $48.44 | +21.07% | ABOVE |
| 150 SMA | $45.99 | +27.50% | ABOVE |
| 200 SMA | $42.98 | +36.44% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is PAHC in an uptrend right now?
PAHC has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, PAHC is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is PAHC overbought or oversold?
PAHC's RSI (14) is 54. The stock is in neutral territory, neither overbought nor oversold.
Is PAHC outperforming the market?
PAHC has a Relative Strength (RS) Rating of 82 out of 99. Yes, PAHC is a market leader, outperforming 82% of all stocks over the past 12 months.
Where is PAHC in its 52-week range?
PAHC is trading at $58.64, which is 98% of its 52-week high ($60.08) and 96% above its 52-week low ($19.00).
How volatile is PAHC?
PAHC has a Beta of 1.38 and 52-week volatility of 52%. It's more volatile than the S&P 500 - expect bigger swings.